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table coronary artery disease1 (CAD) or stable ischemic
heart disease2 are terms preferred in Europe and the
United States, respectively, that generally refer to the same
patients––those with angina, its equivalent, or no symptoms
who experience episodes of reversible myocardial supply:
demand mismatch in the absence of acute myocardial
infarction (MI) or unstable angina. Although the exact number
is unknown, nearly 300 000 percutaneous coronary interventions (PCIs) for stable CAD are performed annually on
inpatients in the United States.3,4 A signiﬁcant and increasing
number of additional PCIs for stable CAD are performed on
outpatients, but these numbers are not available. Despite
randomized controlled trials and meta-analyses of these trials
demonstrating that an initial strategy of PCI for stable CAD
does not improve survival or prevent MI beyond what is
achieved by optimal medical therapy (OMT),5–18 more than
half of these procedures are performed on patients not
treated with OMT.19 Numerous explanations related to
physician behavior or the healthcare environment have been
advanced to explain the deviation of practice from the
evidence.20 However, a broader perspective indicates that the
current stable CAD paradigm wherein the epicardial stenosis
is the proximate cause of angina, ischemia, MI, and death and
those outcomes can be prevented by revascularization is the
product of 500 years of scientiﬁc thought.

History of the Current Paradigm
Although atherosclerosis has been described since antiquity,
the intellectual birth of the epicardial stenosis paradigm can
be traced to the early 1500s when Leonardo da Vinci
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recognized the degeneration of blood vessels with age during
autopsies he personally performed. He described the continuous narrowing of the lumen associated with the “thickening
of the coats” of arteries.21 While he determined that this
process led to death in some individuals, he attributed it to
the natural aging process rather than disease.21 Unfortunately, his observations were recorded in private journals that
were not published until the 1800s.
In 1698, 70 years after Harvey conceptualized the circulatory system,22 Chirac demonstrated the importance of
coronary blood ﬂow on cardiac function when he observed
that the canine heart stopped beating after the coronary
arteries were ligated (Figure 1).23 William Heberden subsequently characterized the syndrome of angina pectoris in
176824 but was unable to connect it to Chirac’s previous work
or to determine the underlying cause.
The link to atherosclerosis, that da Vinci had initially hinted
at in the 1500s, would be discovered by Edward Jenner when he
ﬁrst ascribed angina to underlying atherosclerosis after
correlating clinical symptoms with autopsy ﬁndings.24 In a
1777 letter to Heberden, Jenner described “a kind of ﬁrm,
ﬂeshy tube, formed within the vessel, with a considerable
quantity of ossiﬁc matter dispersed irregularly through it.”24
Jenner’s schoolmate, Caleb Parry, reasoned that a supply:
demand mismatch during exertion caused angina, likely related
to ﬂow limitations through the obstructed coronary arteries
that Jenner described.25 Ironically, Jenner’s mentor, the
renowned anatomist John Hunter, developed angina and died
suddenly after an argument at St. George’s Hospital in 1793.24
Jenner noted marked atheroma during Hunter’s autopsy.25
In 1809, Allen Burns, a lecturer in anatomy in Glasgow,
elaborated on Parry’s ideas and asserted that myocardial
ischemia was the likely cause of angina pectoris.25 This theory
would be linked to electrocardiographic ﬁndings in 1928 when
Feil and Siegel attributed ST- and T-wave changes during
exercise in patients with angina to a decrease in blood ﬂow to
the heart.26
The primacy of the epicardial obstruction was emphasized in
a review of 355 cardiac autopsies in 1941 that noted that every
patient who developed angina had an occlusion or marked
narrowing of a coronary artery.27 The serendipitous discovery
of coronary angiography by Sones in 1958 allowed visualization
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Figure 1. Historical development of the epicardial stenosis paradigm. CABG indicates coronary artery
bypass graft; CAD, coronary artery disease; PTCA, percutaneous transluminal coronary angioplasty.

of epicardial CAD in living patients for the ﬁrst time.28
Subsequent landmark angiographic studies documented the
natural history of epicardial CAD and its adverse impact on
survival.29 Around the same time, Robb and coworkers
demonstrated reduced survival in patients with an abnormal
stress test.30 Other studies correlated abnormal exercise
stress test ﬁndings with the presence of obstructive CAD.31
With the ﬁrst human coronary artery bypass by Goetz in
196032 and the ﬁrst percutaneous transluminal coronary
angioplasty (PTCA) by Gr€untzig in 1977,33 physicians could,
for the ﬁrst time, bypass or dilate the epicardial stenosis and,
consistent with the existing paradigm, alter the course of the
disease. By the early 1980s, through a unique collaboration of
physicians, hospitals, and industry that has been referred to
as the medical-industrial complex,34 an efﬁcient system had
been created to identify and treat the millions of patients with
obstructive CAD. Despite early warnings that the enthusiasm
for revascularization surpassed the evidence,35,36 coronary
bypass surgery and PCI soon became two of the most
commonly performed procedures in the United States and
throughout the world.

Challenges to the Paradigm
Prevention of Death and MI
The ﬁrst trial comparing PTCA with medical therapy in
patients with stable CAD, the 1992 ACME (Angioplasty
Compared to Medicine) study randomized 212 patients with
single-vessel CAD to PTCA or medical therapy.5 PTCA resulted
DOI: 10.1161/JAHA.117.007006

in greater freedom from angina (64% versus 46%) and exercise
tolerance at 6 months but did not reduce mortality or MI,
although the study was not powered for these outcomes.
Subsequent trials were consistent in demonstrating greater
but far from universal short-term angina relief with PTCA than
medical therapy but no reduction in mortality or MI.6–10
The results of the early studies led some to argue that the
failure of PTCA to improve hard outcomes (death or MI) was
attributable to the inclusion of patients at low risk. MASS
(Medicine Angioplasty and Surgery Study), therefore, only
included patients with proximal left anterior descending
coronary artery (LAD) stenosis, yet still found no reduction in
mortality or MI with PTCA.6 These early PTCA trials came before
the advent of stenting; medical therapy in this era was limited to
antianginal medications such as b-blockers and nitrates.
Among these early trials, the RITA-2 (second Randomised
Intervention Treatment of Angina) was the ﬁrst large (>1000
patients) investigation to compare PTCA with medical therapy.
Despite medical therapy that was rudimentary by today’s
standards, death or deﬁnite MI were less frequent with
medical therapy than PTCA (3.3% versus 6.3%) (relative risk,
1.92; 95% conﬁdence interval [CI], 1.08–3.41 [P=0.02]).
Angina improved in both groups but more so with PTCA.
Compared with the PTCA group, there was a 16.5% absolute
excess of grade 2 or worse angina in the medical group
3 months after randomization (P<0.001), which attenuated to
7.6% after 2 years. Bare-metal stents were introduced at the
end of the trial and were only used in 9% of procedures.
It was anticipated that the newly available bare-metal
stents would improve outcomes by providing a larger lumen
Journal of the American Heart Association
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Angina
PCI has been shown to provide incremental, short-term relief
of angina compared with medical therapy that is far from
universal as would be expected according to the prevailing
paradigm. In MASS-II,11 the BARI 2D (Bypass Angioplasty
Revascularization Investigation 2 Diabetes) trial,44 and
COURAGE,45 only 7% to 17% more patients in the PCI arm
were free from angina at 12 months compared with patients
randomized to medical therapy alone. In MASS-II, the
incremental beneﬁt of PCI persisted for 120 months.41 By
24 months in BARI 2D44 and by 36 months in COURAGE,45
freedom from angina was not signiﬁcantly different between
DOI: 10.1161/JAHA.117.007006

PCI and medical therapy groups. The percentage of patients
treated with PCI who continued to have angina at 1 year
ranged from 45% in MASS-II (class II or III angina) to 60% in
BARI 2D to 68% in COURAGE.
One month after relieving the ﬂow-limiting stenosis by
stent placement in COURAGE, 79% of patients with baseline
angina still had angina45 (Figure 3), suggesting that, in most
COURAGE patients, the epicardial stenosis was not the cause
of angina. There was only an 11% advantage of PCI over the
medical therapy arm in angina relief at 1 month with a
diminishing beneﬁt over time. The recently reported ORBITA
(Objective Randomised Blinded Investigation With Optimal
Medical Therapy of Angioplasty) trial, a randomized doubleblind, sham-controlled trial of PCI and medical therapy in
patients with angina and single-vessel CAD refractory to OMT
found no beneﬁt of PCI in change in exercise time, angina
relief, angina frequency, angina stability, time to 1 mm of ST
depression, quality of life or treatment satisfaction.46 These
results suggest that prior studies that reported greater
angina relief from PCI compared to medical therapy were
confounded by the placebo effect associated with unblinded
PCI and raise the question of whether PCI is associated with
any incremental improvement in angina relief compared to
OMT.46

High-Risk Subgroups
As was the case with the early PTCA trials, the results of
randomized trials of PCI and medical therapy were downplayed because it was believed that patients at high risk had
not been enrolled. However, patients at high risk including
those with diabetes mellitus, proximal LAD lesions, reduced
ejection fraction, multivessel CAD, increased age, chronic
kidney disease, and signiﬁcant myocardial ischemia have
been included in recent trials.

Diabetes mellitus
BARI 2D randomized 2368 patients with type 2 diabetes
mellitus and stable CAD to prompt revascularization with
intensive medical therapy or intensive medical therapy
alone.15 After 5 years, there was no difference in mortality
or in major adverse cardiovascular events between initial PCI
and medical therapy groups. Subsequent analyses found no
difference between initial PCI and medical therapy regardless
of the number of diseased vessels, the amount of jeopardized
myocardium, the number of stenotic lesions, the presence of
a total occlusion, proximal LAD disease, prior revascularization, or an abnormal left ventricular ejection fraction.47 While
the patients at higher risk with diabetes mellitus had more
adverse cardiovascular events, those events were not
prevented or reduced by PCI.
Journal of the American Heart Association
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and a more durable angiographic result than PTCA. The ﬁrst
trial to more uniformly include stents, MASS-II, randomized
611 patients with stable CAD and proximal LAD stenosis to
coronary artery bypass grafting (CABG), PCI (72% received
stents), or medical therapy.11 Compared with PCI, medical
therapy reduced the composite end point of cardiac mortality,
MI, or refractory angina. MASS-II, along with the trial by
Hambrecht13 also published in 2004, were the ﬁrst trials to
include disease-modifying statins and angiotensin-converting
enzyme inhibitors in the medical therapy regimen. In MASS-II,
there remained no difference in overall mortality between the
3 groups after 10 years of follow-up.
The landmark COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation) trial,
published in 2007, was a multicenter randomized trial that
compared an initial strategy of PCI with protocol-mandated
optimal medical therapy (OMT) with OMT alone in 2287
patients with angina or objective evidence of ischemia and
signiﬁcant CAD (>70% stenosis).12 Patients randomized to
OMT were permitted to cross over to PCI for refractory
angina. After 4.6 years, there was no difference in death or
nonfatal MI between the two groups (hazard ratio [HR] for the
PCI group, 1.05; 95% CI, 0.87–1.27; P=0.62), with a 30%
cross-over rate from the OMT group to PCI.
None of the trials comparing an initial strategy of PCI with
stents and medical therapy to medical therapy alone in stable
CAD11–16 nor a 2012 meta-analysis17 have shown that PCI
improves survival (combined odds ratio [OR], 0.98; 95% CI,
0.83–1.15)17 or reduces MI (combined OR, 1.12; 95% CI,
0.93–1.34).17 We performed an updated meta-analysis of all
published trials randomizing patients to an initial strategy of
PCI (with or without stents) in addition to medical therapy
compared with medical therapy alone using the longest
published follow-up available.8,9,12–15,37–43 The analysis continues to show no improvement in survival (Figure 2A) and no
reduction in nonfatal MI (Figure 2B). These results persisted
even after limiting the analysis to the trials that only included
stents (data not shown).
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Figure 2. A, Difference in survival in randomized controlled trials comparing initial percutaneous coronary intervention (PCI) vs medical
therapy (MT). A systematic search of published studies in any language in MEDLINE, Cochrane, and PubMed from 1970 to October 2017 was
performed independently by both authors using the following search terms: stent, medical therapy, stable angina, coronary artery disease (CAD),
and combinations of these terms. Patient outcomes (death from any cause and nonfatal myocardial infarction) were systematically reviewed and
recorded independently by both authors. A meta-analysis of summary statistics from individual trials was performed using Comprehensive MetaAnalysis software, version 2 (Biostat Inc). Summary odds ratios (ORs) were calculated using a random-effects model. Results from the longest
reported follow-up are shown.8,9,13–15,37–43 All included studies are listed by name along with point estimates of the ORs and respective 95%
conﬁdence intervals (CIs). The red squares represent the overall ﬁndings in each plot. B, Difference in nonfatal myocardial infarction in
randomized controlled trials comparing initial PCI vs MT. Results from the longest reported follow-up are shown.8,9,12–15,37–42 All included
studies are listed by name along with point estimates of the ORs and respective 95% CIs. The red squares represent the overall ﬁndings in each
plot.

Proximal LAD
In COURAGE, although survival free of death, MI, or acute
coronary syndrome was reduced in all patients with a
DOI: 10.1161/JAHA.117.007006

proximal LAD stenosis >90%, PCI did not improve these
outcomes (P=0.79).48 These results align with the earlier
ﬁndings of MASS,6 which included patients with >80%
Journal of the American Heart Association
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Figure 3. The incremental beneﬁt of percutaneous coronary intervention (PCI) and optimal medical
therapy (OMT) compared with OMT alone in patients with baseline angina in the COURAGE (Clinical
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. The percentage of patients
with angina over time from baseline to 36 months is displayed. One month after PCI, 79% of patients with
baseline angina still had angina in the PCI arm, an 11% incremental beneﬁt relative to the OMT arm. At
36 months, there was no signiﬁcant difference between groups.

proximal LAD stenosis, and MASS-II,11 which required >70%
proximal LAD stenosis and documented ischemia. Neither
study found that PCI resulted in any reduction in cardiovascular events.

anecdotal experience, they are not subject to selection or
recall bias. Across the numerous high-risk subsets evaluated,
there has never been any signal suggestive of an improvement
in outcomes with PCI that would justify an appropriately
powered randomized trial.

Three-vessel CAD and low ejection fraction
In a subgroup analysis of COURAGE, an increasing number of
diseased vessels and/or the presence of reduced ejection
fraction were associated with signiﬁcant reductions in eventfree survival.49 In the patients at highest risk with 3-vessel
CAD and reduced ejection fraction (n=124), there was no
beneﬁt from initial PCI and OMT compared with OMT alone
(P=0.59).

Other high-risk groups
Additional analyses of COURAGE have found no beneﬁt for an
initial strategy of PCI in patients with a recent acute coronary
syndrome or class III angina,50 older patients,51 or patients
with chronic kidney disease.52 As expected, each high-risk
subgroup experienced worse outcomes, but PCI did not
improve these outcomes for any subgroup. Although these
hypothesis-generating post hoc analyses are limited by their
small sample size, the sample sizes are larger than the
anecdotal experience of most individual physicians, and unlike
DOI: 10.1161/JAHA.117.007006

CAD before vascular surgery
Given the hemodynamic stress of vascular and other major
noncardiac surgeries, prophylactic coronary revascularization
is often pursued in the hope of reducing postoperative
ischemic events. No beneﬁt of prophylactic PCI (or CABG) was
shown in the CARP (Coronary Artery Revascularization
Prophylaxis) trial in which patients with >70% stenosis of at
least one coronary vessel (n=510) were randomized to
revascularization before vascular surgery for an expanding
abdominal aortic aneurysm (33%) or arterial occlusive disease
of the legs (67%).53 In the revascularization group, 59%
underwent PCI and 41% underwent CABG. There was no
difference in postoperative mortality between the revascularization and medical therapy groups. No high-risk subset that
beneﬁted from revascularization could be identiﬁed, including
patients with a moderate or large degree of ischemia, a
greater revised cardiac risk index, or 3-vessel CAD and left
ventricular dysfunction.
Journal of the American Heart Association
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Myocardial ischemia on stress testing has long been associated with increased mortality.54 In a recent review it was
asserted that “the presence and extent of ischemia is the
most important factor related to outcome and that all
functionally signiﬁcant stenoses should be revascularized to
relieve ischemia.”55 However, closer examination of the
evidence base used to support this opinion ﬁnds it is of
insufﬁcient quality to justify such a reﬂexive approach to
treatment of patients with stable CAD and ischemia. Furthermore, closer review of the data suggests that ischemia is a
marker for adverse outcomes rather than the cause of the
adverse outcomes (analogous to ventricular ectopy after
MI56).
The belief that ischemia necessitates revascularization to
improve outcomes can be traced, in part, to a retrospective
analysis of the CASS (Coronary Artery Surgery Study) registry
that reported the beneﬁt of bypass surgery was greatest in
patients who were unable to exercise beyond stage 1 due to
angina and displayed 1 mm of ST depression.57
Hachamovitch et al58 subsequently performed a singlecenter, retrospective review of 10 627 patients who underwent an exercise or adenosine stress myocardial perfusion
scan between 1991 and 1997. After a mean follow-up of
1.9 years, Cox proportional hazards modeling indicated that
the 671 (6.3%) patients who underwent revascularization
(PCI in 346, CABG in 325) within 60 days experienced
improved cardiac survival if their ischemic burden was 10%
to 12.5%, but worse cardiac survival if their ischemic burden
was <10%.
As a retrospective analysis, this study cannot assess
causality. Furthermore, it was subject to methodological ﬂaws
including short follow-up and signiﬁcant selection bias that
severely limited the interpretation of its ﬁndings. Their model
included degrees of myocardial ischemia up to 50% that are
not seen clinically. In addition, there was no uniformly
prescribed medical therapy that would be considered optimal
by modern standards. Although this article is widely quoted to
justify revascularization in the presence of ischemia, to our
knowledge it has never been used to justify avoidance of
revascularization in patients with an ischemic burden <10%.
An analysis of 314 patients from COURAGE who underwent nonprotocol-mandated rest/stress myocardial perfusion
scans before and after randomization found that patients with
>5% reduction in ischemia on follow-up imaging (regardless of
treatment strategy) had a lower risk for death or MI in an
unadjusted analysis (P=0.037).59 However, this ﬁnding did not
persist in an adjusted analysis (P=0.26). The unadjusted
outcome data from this small cohort of patients continue
to be used to justify the use of PCI for patients with ischemia.
DOI: 10.1161/JAHA.117.007006

The COURAGE investigators subsequently reviewed the
1381 randomized patients who underwent myocardial perfusion scans at baseline.60 Of these, 486 had moderate to
severe ischemia, evenly divided between the randomized
treatment groups. There was no difference in outcomes in
patients with moderate to severe ischemia randomized to
treatment with PCI and OMT compared with OMT alone.
Similarly, the nuclear substudy of 1505 patients from BARI 2D
found no relationship between ischemic myocardium and
subsequent death or MI.60
A 2014 meta-analysis reported outcomes of patients with
baseline ischemia or an abnormal fractional ﬂow reserve (FFR)
in the randomized trials comparing PCI and medical therapy
with medical therapy alone.18 There was no difference in
death, MI, unplanned revascularization or angina between
groups (Figure 4). The strong association of ischemia with
impaired event-free survival coupled with the lack of beneﬁt of
PCI in patients with ischemia suggests that ischemia is a
marker of adverse outcomes rather than the cause of the
adverse outcomes. The extent of ischemia is correlated with
atherosclerotic plaque burden61 that, as the substrate for
acute coronary syndromes, may be the underlying determinant of prognosis and the explanation for why PCI offers no
incremental beneﬁt beyond optimal disease-modifying therapy. In further support of this theory, in COURAGE,
atherosclerotic burden was independently predictive of
adverse outcomes, whereas ischemic burden was not.62

Invasive Physiologic Tools to Assess
Hemodynamic Signiﬁcance of Epicardial CAD
FFR was developed as an invasive tool to quantify the
hemodynamic signiﬁcance of an angiographic stenosis under
the assumption that revascularization of hemodynamically
signiﬁcant lesions will improve outcomes––in other words, to
replace the “oculostenotic” reﬂex with an “ischemia-PCI”
reﬂex. FFR estimates ﬂow across a lesion by measuring the
change in pressures between the aorta and the coronary
artery distal to a lesion during pharmacologically induced
maximal coronary ﬂow.63 The impetus for its development
was recognition of the limited accuracy of angiographic
assessment of lesion severity. FFR was calibrated against
stress testing to derive a cutoff value that correlates best with
ischemia. Originally an FFR <0.75 was found to accurately
predict at least one positive stress test in patients undergoing
an exercise test, thallium scan, and dobutamine stress
echocardiogram.64 However, contemporary stress tests were
validated against coronary angiography whose limitations
stimulated the development of FFR in the ﬁrst place. Thus, the
logic justifying FFR appears circular, at best.
In the FAME (Fractional Flow Reserve versus Angiography
for Multivessel Evaluation) trial, 1005 patients were
Journal of the American Heart Association
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Figure 4. Comparison of percutaneous coronary intervention (PCI) and medical therapy (MT) vs MT alone in
patients with documented myocardial ischemia. Each graph illustrates an outcome. A, Death; B, nonfatal myocardial
infarction; C, unplanned revascularization; and D, angina during follow-up. All included studies are listed by name
along with point estimates of the odds ratios (ORs) and respective 95% conﬁdence intervals (CIs). The sizes of the
squares denoting the point estimate in each study are proportional to the weight of the study. The diamonds
represent the overall ﬁndings in each plot. See text for full trial names. Reproduced from Stergiopoulos et al18 with
permission. Copyrightª2014 American Medical Association. All rights reserved.

randomized to angiographically guided PCI or PCI guided by
an FFR <0.80 (it is not clear why 0.75 was not used). FFRguided PCI was associated with fewer PCIs and a reduction in
the combined end point of death, MI, or revascularization at
2 years.65 Often overlooked, the FAME trial was the ﬁrst
study to demonstrate harm from unnecessary PCI in patients
with stable CAD. It left unanswered where the line is drawn
between necessary and unnecessary PCI.
The FAME 2 trial provided insight into where that line
should be drawn. This unblinded trial randomized 888 patients
with FFR <0.80 to initial PCI with second-generation drugeluting stents and medical therapy versus medical therapy
alone.16 There was no difference in death or MI between
groups at a follow-up of 2 years.42 FAME 2 enrolled a very
low-risk population: there were only 6 deaths (1.3%) in the PCI
group and 8 deaths (1.8%) in the medical therapy group,
including only 3 cardiac deaths in each group at 2 years
(0.7%).40 In an effort to demonstrate some beneﬁt of PCI on
important end points, FAME 2 included a landmark analysis
that excluded events that occurred in the ﬁrst 7 days
following randomization including periprocedural MI that can
only occur in the PCI-treated patients. By eliminating
periprocedural MI from end point analysis, the authors
showed a reduction of MI in the PCI group.40 However, FAME
DOI: 10.1161/JAHA.117.007006

2 deﬁned MI, including periprocedural MI, as CKMB >10 times
the upper limits of normal or >5 times upper limits of normal
with an associated occluded artery or new Q waves, a
threshold clearly associated with increased 30-day
mortality.63,64
FAME 2 was initially designed to randomize 1600 patients
with a planned follow-up of 5 years. The study was terminated
prematurely at the recommendation of the data safety
monitoring board after 213 days of follow-up with only 888
patients randomized because the composite end point
favored the FFR-guided PCI group, but the end point
difference was driven solely by urgent revascularization.
Notably, 52% of the “urgent” revascularizations in the initial
analysis14 and 49% of urgent revascularizations at 2-year
follow-up40 were not associated with either ischemic ST-T–
wave changes or positive cardiac biomarkers. The increase in
urgent revascularization in the medical therapy group appears
to have been largely driven by the subset of patients with FFR
<0.65 (P=0.01 for interaction)14 indicative of such a severe
stenosis that passage of the ﬂow wire across the lesion
without stent placement may have resulted in plaque
disruption.62 Patients in the medical therapy arm were not
treated with dual anti-platelet therapy which may have
protected against events caused by iatrogenic plaque injury.
Journal of the American Heart Association
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Concern for Harm
Even with the lack of documented beneﬁt for an initial PCI
strategy in patients with stable CAD, some argue that it is
reasonable to still pursue initial PCI since randomized trials
have shown that it can improve or relieve angina in some
patients with no increase in MI or death. It is important to
note that PCI does carry with it a low, but real, risk of
complications including death (0.65%), MI (15%), renal injury
(13%), stroke (0.2%), contrast allergy (≤1%), and vascular
complications (2–6%).4,67,68 While there was no difference in
overall death or MI in the randomized trials of PCI versus
medical therapy, the studies were not powered to detect an
increase in uncommon but unavoidable procedural complications. These seemingly low risks are put in perspective when
they are multiplied by the estimated 300 000 PCI procedures
performed annually in the United States for stable CAD. Given
the added cost69 and procedure-related risks associated with
PCI, as well as the limited improvement in angina compared
with OMT, it is difﬁcult to argue that equipoise exists in the
selection of an initial treatment strategy for patients with
stable CAD.

Paradigm Change
The centuries-old paradigm that the epicardial stenosis leads
to ischemia and angina has led to the labeling of patients with
ischemia on stress testing but no epicardial stenosis as
having a false-positive stress test result. However, up to 50%
of patients with angina and an abnormal stress test do not
have obstructive CAD.70 Despite the absence of obstructive
DOI: 10.1161/JAHA.117.007006

CAD, these patients experience increased event rates including mortality.71,72 These ﬁndings, in combination with the
persistent inability of PCI to prevent death or MI or eliminate
angina in patients with stable CAD, ﬁrmly argue against the
current paradigm that the epicardial stenosis leads to
ischemia and angina in a 1:1 relationship and, eventually,
MI and death.
In his seminal book, The Structure of Scientiﬁc Revolutions,
Thomas Kuhn argued that scientiﬁc progress was not simply an
incremental process marked by the steady accumulation of
more data.73 Instead, revolutionary periods in thought occur
when the weight of new evidence forces the scientiﬁc
community to abandon their formerly held beliefs. Tossing
aside previous assumptions, scientists then form a new
paradigm that encapsulates the entirety of the knowledge and
understanding of the time. We and others believe the weight of
data indicates it is time for construction of a new paradigm.74,75

A New Paradigm: Chronic Ischemic Coronary
Syndromes
Ischemia, by deﬁnition, is a reduction in blood supply to cells
resulting in a lack of sufﬁcient oxygen for oxidative
metabolism. Ischemia can, therefore, result from dysfunction
anywhere along the vascular delivery conduit from the aorta
to the microvasculature. The recognition of the multiple
mechanistic causes of ischemia, angina, and cardiovascular
events in stable CAD suggest it would be more appropriately
and accurately referred to as a “syndrome” than a “disease.”
Thus, a chronic ischemic coronary syndrome (CICS) can
originate from ﬂow obstruction, endothelial dysfunction or
spasm of the epicardial vessels, and/or the microvasculature
that is responsible for 80% of the resistance to coronary ﬂow
(Table). Further elaboration on microvascular dysfunction is
beyond the scope of this review but the topic has recently
been thoroughly reviewed.76
Fully adopting the new paradigm will require a seismic
change in our approach to patients with CICS. The optimal
initial approach to patients with a CICS that can safely rule
out signiﬁcant pathology, such as left main disease, but
reduce unnecessary catheterizations and interventions needs
to be determined. New diagnostic tools need to be created
and reﬁned to more accurately diagnose endothelial dysfunction, microvascular dysfunction, and coronary spasm.76 New
therapies need to be developed that can better treat the
multitude of pathologies that contribute to the CICS. Most
importantly, we need to do a better job of using the tools we
already have. OMT is a powerful intervention, yet only 29% of
patients in the SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery) trial77
at baseline were on OMT, with only 35% to 40% on OMT
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In addition, the unblinded nature of the trial may have
prompted more aggressive evaluation and treatment of
patients with very low FFR values who were randomized to
medical therapy.
There were 42 more urgent revascularizations in the
medical therapy arm than the FFR-PCI arm (7 versus 49). By
suggesting that the results of FAME 2 support PCI of every
lesion with an FFR <0.8 is to suggest that to prevent urgent
revascularizations (but not MI and death) in the additional
9.5% of patients who experienced them in the medical arm,
100% of patients with an abnormal FFR should undergo PCI.
This is not a wise use of resources and recalls the lesson of
FAME: unnecessary stenting leads to worse outcomes. Finally,
it must be acknowledged that FFR is not a benign procedure.
Coronary artery dissection, abrupt vessel closure, and death
have been caused by measuring FFR. A French trial of FFR
versus angiographic guidance for PCI in multivessel disease
was terminated prematurely in 2016 because of excess
deaths (17 versus 7) in the FFR arm at 12 months.66
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Location of Defect

Potential Mechanisms

Selected Etiologies

Coronary
macrovessels

Flow-limiting stenosis

Atherosclerosis

Endothelial dysfunction

Atherosclerosis,
viruses

Spasm

Atherosclerosis,
cocaine

Muscle bridging
Aberrant origin

Coronary
microvessels
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Noncoronary
arteries

Dissection

Pregnancy, trauma,
Marfan syndrome

Inflammation

Cardiac transplant,
collagen diseases

Microvascular
dysfunction

Atherosclerosis

Endothelial
dysfunction

Atherosclerosis

Spasm

Atherosclerosis

Inflammation

Cardiac transplant,
collagen diseases

Microemboli

Atherosclerosis,
atrial fibrillation

Capillary insufficiency

Left ventricular
hypertrophy

Increased stiffness
(increased afterload)

Calcification, aging,
hypertension,
chronic kidney
disease

Adapted from Pepine and Douglas74 with permission. Copyright©2012 Elsevier.

5 years after revascularization. Patients receiving OMT experienced a 36% relative reduction in mortality over 5 years (HR,
0.64; 95% CI, 0.48–0.85 [P=0.0002]).

Indication for Revascularization
While we have focused on the lack of evidence for PCI
improving clinical outcomes in patients with stable CAD and
the need for a new paradigm, it is important to note that this
discussion does not mean to imply that revascularization does
not improve outcomes in many patients with CAD including
those with acute coronary syndromes and severe stenosis of
the left main coronary artery and selected patients with a
CICS. In certain patients with CICS, CABG in combination with
OMT has been shown to improve outcomes compared with
OMT alone. For example, a patient-level pooled analysis of
5034 patients with diabetes mellitus with stable CAD from
BARI 2D, COURAGE, and the FREEDOM (Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal
Management of Multivessel Disease) trial78 demonstrated
DOI: 10.1161/JAHA.117.007006

that CABG and OMT were superior to OMT alone for reduction
in the primary outcome of death, MI, and stroke (HR, 0.79;
95% CI, 0.64–0.97 [P=0.022]) including a reduction of MI
alone (HR, 0.55; 95% CI, 0.41–0.74 [P=0.0001]) at a median
follow-up of 4.5 years. The primary outcome was largely
driven by the decrease in MI, with no difference in mortality
between groups and a trend toward increased stroke in the
CABG group. CABG plus OMT was superior to PCI plus OMT
for the primary end point (HR, 0.71; 95% CI, 0.59–0.85
[P=0.0002]), death (HR, 0.76; 95% CI, 0.60–0.96 [P=0.024]),
and MI (HR, 0.50; 95% CI, 0.38–0.67 [P=0.0001]), but not
stroke (HR, 1.54; 95% CI, 0.96–2.48 [P=0.074]).
These results are consistent with the hypothesis that
atherosclerotic burden is the primary determinant of outcome. PCI treats a discrete lesion in a coronary artery while
leaving large portions of diseased coronary arteries untreated.
CABG, on the other hand, provides a vascular conduit around
much of the diseased vessel with its numerous atherosclerotic plaques that form the substrate for plaque disruption,
thrombosis, and MI.

Conclusions
Despite multiple trials, there is no evidence that a strategy of
PCI and OMT improves cardiovascular outcomes in patients
with CICS compared with OMT alone. Furthermore, multiple
analyses have failed to identify a single high-risk subset that
beneﬁts from a strategy of initial PCI. The ORBITA study
requires conﬁrmation in other populations but calls into
question the value of PCI in treating refractory angina. A more
intense effort should be made toward improving preventive
care and maximizing use of proven medical therapy, which
remains woefully underutilized in the modern era in patients
with CICS. Given the failings of the epicardial stenosis
paradigm, it is time to embrace a new, more enlightened
paradigm that considers the many other known causes of
myocardial ischemia including vasospasm, microvascular
angina, and endothelial dysfunction in the evaluation of every
patient with angina or ischemia (Table). Curtailing unnecessary PCI has the potential to allow a shift of resources toward
gaining a greater understanding of the causes, diagnosis,
prevention, and treatment of the CICS (Table).
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